adalimumab + golimumab + infliximab

This is a combination of three monoclonal antibody drugs—adalimumab, golimumab, and infliximab—all of which are anti-tumor necrosis factor alpha (anti-TNFα) agents. Each drug individually binds to and neutralizes tumor necrosis factor alpha (TNFα), a pro-inflammatory cytokine involved in the pathogenesis of several autoimmune diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis. These agents reduce inflammation by blocking TNFα-mediated signaling pathways that drive immune cell activation and inflammatory cytokine production. The combination of these three specific anti-TNF monoclonal antibodies is not an established or approved therapeutic regimen; there are no clinical guidelines or evidence supporting their concurrent use together due to overlapping mechanisms and increased risk for immunosuppression. Each agent has been developed independently for similar indications but is typically used as monotherapy or in combination with non-biologic immunosuppressants.